MHRA – Page 206 – Pharma.Tips

Particulate Matter Oos during hold-time study: how to classify deviation and set disposition

Classifying Deviations from OOS Results of Particulate Matter During Hold-Time Studies In the realm of pharmaceutical manufacturing, maintaining compliance with stringent regulatory standards is paramount. An unexpected Out-of-Specification (OOS) result…

Tube Leakage Complaint in cream manufacturing: complaint trending and risk-based actions

Investigating Tube Leakage Complaints in Cream Manufacturing: Trending and Risk Mitigation Strategies In the realm of pharmaceutical manufacturing, particularly in topical dosage forms such as creams, tube leakage complaints can…

Filter Integrity Failure during power interruption: facility, people, process root cause mapping

Understanding Filter Integrity Failure During Power Interruptions: A Comprehensive Root Cause Investigation Filter integrity failures during power interruptions can lead to significant deviations and contamination risks in pharmaceutical manufacturing, particularly…

Bioburden Spike Pre-Filtration during routine EM trending: data integrity checks for lab and shop floor

Addressing Bioburden Spikes Before Filtration: Ensuring Data Integrity in Environmental Monitoring Trending In pharmaceutical manufacturing, particularly within sterile environments, bioburden control is paramount. Bioburden spikes detected during routine environmental monitoring…

Color Change during method transfer: cleaning validation and worst-case selection

Investigating Color Change during Method Transfer in Pharmaceutical Manufacturing Color change during method transfer processes can present significant challenges in pharmaceutical manufacturing, particularly regarding cleaning validation and worst-case scenario selection.…

Em Excursion In Grade A during hold-time study: facility, people, process root cause mapping

Identifying Root Causes of Em Excursion in Grade A during Hold-Time Studies In pharmaceutical manufacturing, maintaining controlled environments is critical to ensuring product quality, especially in the production of parenteral…

Sterility Test Failure post-sterile filtration: risk assessment for patient safety and recall

Assessing Risk and Investigating Sterility Test Failures After Sterile Filtration Sterility test failures following sterile filtration represent a significant concern within pharmaceutical manufacturing, particularly for parenteral dosage forms. Such events…

Cleaning Validation Failure during method transfer: mixing and sampling controls for QA review

Investigating Cleaning Validation Failures During Method Transfer: Key Controls and CAPA Insights In pharmaceutical manufacturing, especially in topical and dermatological dosage forms, maintaining rigorous cleaning validation protocols is critical. A…

Bioburden Spike Pre-Filtration during power interruption: facility, people, process root cause mapping

Investigating Bioburden Spikes Pre-Filtration During Power Interruptions in Pharmaceutical Manufacturing Bioburden spikes in pharmaceutical manufacturing, particularly during the pre-filtration stage, can pose significant risks to product quality and regulatory compliance.…

Filter Integrity Failure during aseptic filling: FDA/MHRA investigation narrative and batch impact

Investigation of Filter Integrity Failures During Aseptic Filling: An FDA/MHRA Perspective In pharmaceutical manufacturing, particularly within parenteral dosage forms, the integrity of filters during aseptic filling processes is critical. When…

Color Change after packaging change: complaint trending and risk-based actions

Investigating Color Change After Packaging Change in Pharmaceutical Manufacturing In pharmaceutical manufacturing, deviations in product appearance can signal significant underlying issues. A common scenario involves color changes in topical formulations…

Sterility Test Failure during routine EM trending: CAPA package with evidence and effectiveness checks

Sterility Testing Failure Investigations during Routine Environmental Monitoring Trending Sterility test failures during routine environmental monitoring (EM) can significantly disrupt pharmaceutical operations, compromising product safety and leading to regulatory scrutiny.…